Tubulis GmbH

🎯𝗙𝗶𝗿𝘀𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗱𝗮𝘁𝗮 𝗳𝗼𝗿 𝗧𝗨𝗕-𝟬𝟰𝟬 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝗮𝘁 𝗘𝗦𝗠𝗢 Today at ESMO we shared the first clinical data set from our Phase I/IIa trial for TUB-040 in platinum-resistant ovarian cancer (#PROC). The results mark a momentous milestone in our mission to bring next-generation antibody-drug conjugates (#ADCs) to patients with hard-to-treat tumors.     TUB-040 demonstrated robust clinical activity and a favorable safety profile in patients with heavily pre-treated patients, marking the first clinical validation of our proprietary Tubutecan technology.    These findings support the continued development of TUB-040 and underscore the potential of our platform to unlock the full therapeutic potential of ADCs and deliver better outcomes for patients in need.    Read the full data overview in our press release: https://lnkd.in/dKUTimYx

🔊 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗧𝘂𝗯𝘂𝗹𝗶𝘀’ 𝗖𝗘𝗢 𝗶𝗻 𝗔 𝗖𝗮𝗹𝗹 𝗧𝗼 𝗟𝗲𝗮𝗱 𝗣𝗼𝗱𝗰𝗮𝘀𝘁    In the latest episode of LifeScience ORG’s 𝘈 𝘊𝘢𝘭𝘭 𝘛𝘰 𝘓𝘦𝘢𝘥 podcast, our CEO, Dominik Schumacher, shares his insights and experiences in building a global leader in ADC therapeutics development out of a university lab.     Listen in to learn more about the challenges he faced in the early company stages, what he thinks are the key ingredients for a successful company, how he views differences between Europe and the US and why he thinks that failure is actually a good thing.     Thank you to the host, David Kirk, for the great discussion!

🚀 𝗧𝘂𝗯𝘂𝗹𝗶𝘀 𝗰𝗹𝗼𝘀𝗲𝘀 €𝟯𝟬𝟴 (𝗨𝗦𝗗 𝟯𝟲𝟭) 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴    We’re excited to share that we have successfully closed a Series C #financing round, led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management, Ascenta Capital and existing investors.     The proceeds will be used to accelerate the clinical development of our lead antibody-drug conjugate (#ADC) candidate, TUB-040, into earlier lines of therapy and additional tumor indications. Further, the capital will advance our differentiated pipeline, including the clinical-stage ADC candidate TUB-030 as well as several preclinical programs, and expand our proprietary platform technologies to bring ADCs into novel applications.    We are looking forward to working with Lorence Kim and Patrick Heron, who are joining our Advisory Board, strengthening our team as we enter our next growth phase to drive ADC innovation. This financing reflects our team’s dedication and the strong support for our mission to redefine ADC therapies for patients with hard-to-treat tumors.     🤝We want to thank our investors, partners, and the entire Tubulis team that enable us to be at the forefront of the next wave of ADC innovation.

📢 𝗧𝘂𝗯𝘂𝗹𝗶𝘀 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 #𝗘𝗦𝗠𝗢𝟮𝟱! From October 17–21, our team will be in Berlin for this year’s ESMO Congress, ready to connect and share more about our differentiated #ADC pipeline. 📍 𝗪𝗵𝗲𝗿𝗲 𝘁𝗼 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝘂𝘀 𝗢𝗿𝗮𝗹 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:  Don’t miss the oral late-breaking presentation on Sunday, October 19 (10:38–10:43 am) by Principal Investigator Antonio González Martín. He will share first clinical data from our Phase I/IIa NAPISTAR 1-01 study of TUB-040 in platinum-resistant ovarian cancer (#PROC) 𝗕𝗼𝗼𝘁𝗵 #𝟰𝟬𝟰𝟱:  Visit our booth in the northeast part of Hall 4.2 to learn more about our growing pipeline and proprietary technologies, which uniquely position us to unlock the full therapeutic potential of ADCs, transforming the cancer treatment landscape and delivering better outcomes for patients in need If you’re attending #ESMO25, reach out to Mary Ann Lumiqued to schedule a meeting at our booth and learn more about our differentiated approach to #ADCs. 

Our CEO Dominik Schumacher recently sat down with David Kirk for LifeScience ORG's podcast series. Stay tuned for the full episode of "A Call to Lead" coming out next week!

📊 𝗢𝘃𝗮𝗿𝗶𝗮𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 is one of the most aggressive and deadly gynecologic malignancies, with most women diagnosed at an advanced stage when long-term survival prospects are poor² ³. The 5-year relative survival rate is 51.6% across all stages and drops to 31.8% when the cancer has metastasized¹ ².  💉𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 include surgery, platinum-based chemotherapy, and, in some cases targeted therapies such as PARP or VEGF inhibitors. Yet, most patients experience disease relapse, and over time, many tumors eventually become resistant to platinum-based drugs – a condition known as platinum-resistant ovarian cancer, or #PROC ⁴ ⁵ ⁶. ⚠️ 𝗨𝗻𝗺𝗲𝘁 𝗻𝗲𝗲𝗱: For PROC patients, standard treatments like single-agent chemotherapy typically result in a median progression-free survival of just 3-4 months, with overall survival rarely exceeding 12-16 months³ ⁴ ⁵ ⁷. These outcomes have remained largely unchanged, and disease recurrence is almost universal, highlighting the urgent need for new therapeutic options⁴ ⁵ ⁶ ⁷. 🌟 𝗘𝗺𝗲𝗿𝗴𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Next-generation targeted therapies, such as antibody-drug conjugates (ADCs) have the potential to improve anti-tumor activity while reducing toxic side-effects, two critical factors for enhancing treatment durability and long-term disease control. Exploring new modes of actions and broadly shared target molecules could help to address the high heterogeneity of ovarian cancers, a major cause for the high relapse/resistance rate in this tumor type. Tubulis is applying a unique approach to ADC design to develop new treatments for patients with solid tumors with high unmet need, including PROC. Learn more about our approach on our website: https://tubulis.com/

📢 𝗢𝗿𝗮𝗹 𝗹𝗮𝘁𝗲-𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗮𝘁 #𝗘𝗦𝗠𝗢𝟮𝟱: 𝟭𝘀𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗨𝗕-𝟬𝟰𝟬 𝗱𝗮𝘁𝗮 First clinical data from our lead candidate TUB-040 will be presented in a mini oral session by our Principal Investigator, Antonio González Martín, at the upcoming ESMO - European Society for Medical Oncology Congress being held October 17-21, 2025, in Berlin.  The presentation will provide interim data from the dose escalation part of the platinum-resistant ovarian cancer (#PROC) cohort in the first-in-human study with TUB-040. TUB-040 is a next-gen NaPi2b-targeting #ADC using our proprietary Tubutecan platform – enabling high stability, excellent pharmacokinetics, and a high drug-to-antibody ratio (DAR8). Stay tuned to learn more about the detailed data, which we will announce in a press release following the presentation at ESMO. 📄Find the abstract details in the press release: https://lnkd.in/dWi5F4rU

Congratulations to our CEO Dominik Schumacher on being appointed to the board of BIO Deutschland e. V.! A strong voice for the future of biotech – we're proud to see this important contribution to our industry. 👏🧬 

🎙𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗼𝘂𝗿 𝗹𝗲𝗮𝗱 𝗔𝗗𝗖 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗧𝗨𝗕-𝟬𝟰𝟬    At Tubulis, we deploy our unique approach to #ADC design to develop highly differentiated ADCs addressing a broad range of solid tumors. Our lead program, TUB-040, exemplifies this strategy. 🔬𝗛𝗼𝘄 𝗶𝘁 𝘄𝗼𝗿𝗸𝘀:  TUB-040 is directed against NaPi2b, an antigen that is overexpressed in ovarian cancer and lung adenocarcinoma and other solid cancer types, but remains minimally expressed in healthy tissues.     Built on our proprietary Tubutecan platform, TUB-040 combines our P5 conjugation technology with the topoisomerase I inhibitor payload exatecan. This enables excellent stability and pharmacokinetics, a high drug-to-antibody-ratio (DAR8), and maximized on-target delivery of the cytotoxic payload.  Our design allows TUB-040 to precisely target tumor cells, while its bystander effect extends activity in heterogeneous tumors, including those with low NaPi2b expression — a key differentiator for addressing these hard-to-treat indications.    📈𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀:  • Publication of preclinical proof-of-concept results in Molecular Cancer Therapeutics (#AACR), showcasing robust and durable efficacy in patient-derived xenograft models, and a highly favorable tolerability profile.    • Progression into the Phase I/IIa NAPISTAR 1-01 trial, evaluating TUB-040 in platinum-resistant ovarian cancer (#PROC) and relapsed/refractory non-small cell lung cancer (#NSCLC).    • FDA Fast Track designation (June 2024) for PROC, emphasizing the high clinical potential of our approach in this high-need indication.    💡 Based on its best-in-class ADC design, TUB-040 offers the potential to significantly increase the therapeutic window and treatment durability, also in heterogeneous tumors, making it a promising new option for patients who urgently need them.  

🚀 𝗪𝗲’𝗿𝗲 𝗚𝗿𝗼𝘄𝗶𝗻𝗴 𝗮𝗻𝗱 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗢𝘂𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗧𝗲𝗮𝗺! A warm welcome to Halley Gilbert, our new Chief Legal Officer & Chief Operating Officer. Halley joins Tubulis at a pivotal moment in our clinical and operational journey, bringing over 20 years of legal and operational leadership experience in the biopharma industry. Her unique background as an attorney and seasoned biotech executive will be instrumental in shaping our strategy and further expanding our U.S. presence. We look forward to her valuable contributions as we continue to advance our pipeline of next-generation ADCs to deliver meaningful clinical impact for cancer patients.